Plain-English translation of NCT06463444 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether doctors can use artificial intelligence and detailed information about your tumor to predict who will benefit most from a combination of three treatments: a type of chemotherapy called HAIC (hepatic arterial infusion chemotherapy), a targeted therapy drug called Lenvatinib, and an immunotherapy drug (a PD-1 inhibitor). The goal is to personalize liver cancer treatment so each patient gets the combination most likely to help them.
Most people are diagnosed with liver cancer at an advanced stage when surgery isn't possible, and doctors currently struggle to predict which patients will respond well to combination treatments. This trial aims to use AI and tumor data to match patients with the treatment most likely to work for them.
If you qualify based on the AI model's analysis of your tumor data, you will receive the three-drug combination treatment (HAIC chemotherapy, Lenvatinib, and a PD-1 inhibitor) at a participating medical center. You will have regular clinic visits and imaging scans to monitor how well the treatment is working and to check for side effects. The trial expects to enroll about 30 patients and will track your response to the treatment over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Chen Xiaoping
Enrollment target
~30 participants
Started
June 2024
Primary completion
June 2025
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
WanGuang Zhang
Tongji Hospital